These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Acid-mediated Lipinski's second rule: application to drug design and targeting in cancer. Omran Z; Rauch C Eur Biophys J; 2014 May; 43(4-5):199-206. PubMed ID: 24687685 [TBL] [Abstract][Full Text] [Related]
23. A perspective on the physicochemical and biopharmaceutic properties of marketed antiseizure drugs-From phenobarbital to cenobamate and beyond. Odi R; Bibi D; Wager T; Bialer M Epilepsia; 2020 Aug; 61(8):1543-1552. PubMed ID: 32614073 [TBL] [Abstract][Full Text] [Related]
24. Selecting the right compounds for screening: does Lipinski's Rule of 5 for pharmaceuticals apply to agrochemicals? Tice CM Pest Manag Sci; 2001 Jan; 57(1):3-16. PubMed ID: 11455629 [TBL] [Abstract][Full Text] [Related]
26. Small molecule kinase inhibitors approved by the FDA from 2000 to 2011: a systematic review of preclinical ADME data. O'Brien Z; Fallah Moghaddam M Expert Opin Drug Metab Toxicol; 2013 Dec; 9(12):1597-612. PubMed ID: 23992134 [TBL] [Abstract][Full Text] [Related]
27. Ask the experts: past, present and future of the rule of five. Baell J; Congreve M; Leeson P; Abad-Zapatero C Future Med Chem; 2013 May; 5(7):745-52. PubMed ID: 23651089 [TBL] [Abstract][Full Text] [Related]
28. In Silico Molecular Docking Analysis of Karanjin against Alzheimer's and Parkinson's Diseases as a Potential Natural Lead Molecule for New Drug Design, Development and Therapy. Gnanaraj C; Sekar M; Fuloria S; Swain SS; Gan SH; Chidambaram K; Rani NNIM; Balan T; Stephenie S; Lum PT; Jeyabalan S; Begum MY; Chandramohan V; Thangavelu L; Subramaniyan V; Fuloria NK Molecules; 2022 Apr; 27(9):. PubMed ID: 35566187 [TBL] [Abstract][Full Text] [Related]
29. Two Decades under the Influence of the Rule of Five and the Changing Properties of Approved Oral Drugs. Shultz MD J Med Chem; 2019 Feb; 62(4):1701-1714. PubMed ID: 30212196 [TBL] [Abstract][Full Text] [Related]
30. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications. DiMasi JA Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388 [TBL] [Abstract][Full Text] [Related]
33. Evaluation of blockbuster drugs under the rule-of-five. Giménez BG; Santos MS; Ferrarini M; Fernandes JP Pharmazie; 2010 Feb; 65(2):148-52. PubMed ID: 20225662 [TBL] [Abstract][Full Text] [Related]
34. Synthesis, structural studies and biological properties of some phosphono-perfluorophenylalanine derivatives formed by S Kwiczak-Yiğitbaşı J; Pirat JL; Virieux D; Volle JN; Janiak A; Hoffmann M; Mrzygłód J; Wawrzyniak D; Barciszewski J; Pluskota-Karwatka D RSC Adv; 2019 Aug; 9(42):24117-24133. PubMed ID: 35527881 [TBL] [Abstract][Full Text] [Related]
35. Design Principles for Balancing Lipophilicity and Permeability in beyond Rule of 5 Space. Möbitz H ChemMedChem; 2024 Mar; 19(5):e202300395. PubMed ID: 37986275 [TBL] [Abstract][Full Text] [Related]
36. Physiochemical property space distribution among human metabolites, drugs and toxins. Khanna V; Ranganathan S BMC Bioinformatics; 2009 Dec; 10 Suppl 15(Suppl 15):S10. PubMed ID: 19958509 [TBL] [Abstract][Full Text] [Related]
37. Overview on the Rule of Five. Pollastri MP Curr Protoc Pharmacol; 2010 Jun; Chapter 9():Unit 9.12. PubMed ID: 22294375 [TBL] [Abstract][Full Text] [Related]
38. Automated selection of compounds with physicochemical properties to maximize bioavailability and druglikeness. Oashi T; Ringer AL; Raman EP; Mackerell AD J Chem Inf Model; 2011 Jan; 51(1):148-58. PubMed ID: 21142079 [TBL] [Abstract][Full Text] [Related]
39. Structural diversity of biologically interesting datasets: a scaffold analysis approach. Khanna V; Ranganathan S J Cheminform; 2011 Aug; 3():30. PubMed ID: 21824432 [TBL] [Abstract][Full Text] [Related]